Financials • Bicara Therapeutics

BCAX

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Payout	DY
12/2022	-38	-12	0%	L	-99	L	-4	-	-33	-0	32	-33	-	-
12/2023	-40	-12	0%	L	-149	L	-230	-	-48	-1	272	-48	-	-
12/2024	-82	-12	0%	L	492	L	-490	-	-82	-0	334	-82	-	-
12/2025	-155	-123	0%	L	401	L	-415	-	-122	-0	32	-122	-	-

To see all financials—including updated, you must be Premium.